BridgeBio Pharma (NASDAQ:BBIO) Given New $107.00 Price Target at Truist Financial

BridgeBio Pharma (NASDAQ:BBIO) had its target price lifted by investment analysts at Truist Financial from $102.00 to $107.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 27.14% from the company’s current price.

A number of other brokerages also recently commented on BBIO. Raymond James Financial downgraded shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Piper Sandler boosted their target price on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a research note on Tuesday. Bank of America increased their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday. Mizuho decreased their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a report on Tuesday, June 16th. Finally, Wells Fargo & Company upped their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a research report on Tuesday. Twenty equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.79.

BridgeBio Pharma Stock Up 0.5%

NASDAQ BBIO traded up $0.46 during trading hours on Wednesday, hitting $84.16. 667,871 shares of the company were exchanged, compared to its average volume of 2,989,727. The company has a 50 day moving average of $76.47 and a two-hundred day moving average of $73.07. BridgeBio Pharma has a 52-week low of $46.81 and a 52-week high of $93.42. The firm has a market cap of $16.45 billion, a price-to-earnings ratio of -23.57 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. During the same period in the previous year, the firm earned ($0.95) EPS. The business’s revenue for the quarter was up 120.4% on a year-over-year basis. On average, equities research analysts predict that BridgeBio Pharma will post -2.31 EPS for the current year.

Insider Buying and Selling

In other news, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $67.46, for a total value of $2,698,400.00. Following the completion of the sale, the chief executive officer directly owned 535,686 shares of the company’s stock, valued at approximately $36,137,377.56. The trade was a 6.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $67.15, for a total value of $671,500.00. Following the transaction, the director owned 11,589 shares in the company, valued at $778,201.35. This represents a 46.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 392,117 shares of company stock valued at $29,934,700 over the last ninety days. Company insiders own 14.23% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Large investors have recently bought and sold shares of the business. Silvant Capital Management LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at about $28,000. Allworth Financial LP purchased a new stake in BridgeBio Pharma during the 2nd quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd acquired a new stake in BridgeBio Pharma during the 3rd quarter worth approximately $34,000. Jones Financial Companies Lllp purchased a new position in shares of BridgeBio Pharma in the 1st quarter valued at approximately $35,000. Finally, Farther Finance Advisors LLC grew its stake in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analyst sentiment strengthened broadly: JPMorgan raised its target to $111 and maintained an “overweight” rating; Canaccord Genuity lifted its target to $106 with a “buy” rating; and TD Cowen, Piper Sandler, Wells Fargo and Bank of America also increased their targets, generally citing improving commercial execution and pipeline potential. Benzinga analyst price-target updates
• Positive Sentiment: Attruby sales surged during the second quarter, with U.S. net sales reportedly increasing 311% year over year. Ex-U.S. Beyonttra royalties also rose 62% sequentially, supporting management’s reaffirmed goal of more than $1 billion in 2026 global Attruby and Beyonttra sales. BridgeBio: Attruby Delivers In Q2
• Positive Sentiment: Revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% year over year. BridgeBio also highlighted expectations for three product launches by mid-2027, adding potential catalysts for the stock. BridgeBio Q2 Earnings Miss, Revenues Beat
• Positive Sentiment: A $1 billion preferred-equity raise is expected to improve BridgeBio’s financial flexibility and help fund commercial expansion and pipeline development.
• Neutral Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees. The grants may help retain talent but create limited potential share dilution. BridgeBio Inducement Grants
• Negative Sentiment: Second-quarter adjusted results were weaker than expected: BridgeBio reported a loss of $0.78 per share versus the $0.58 consensus estimate, despite the substantial revenue beat.
• Negative Sentiment: Morgan Stanley trimmed its price target to $97 from $98, though it retained an “overweight” rating, signaling some caution regarding valuation or execution risks. Benzinga analyst update

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.